Post My Press Release

Free Press Release Distribution

Month: May 2018 (Page 1 of 1191)

Prenatal Care Market: 2017 Research Report Analysis, Size, Share, Growth, Trends and Forecast Opportunities to 2025

Prenatal Care Market: Overview

Prenatal care is the care to be taken during pregnancy. Early and regular prenatal care is quite important for the health of a mom and baby during pregnancy. It includes regular health check-ups and diagnostic tests. The prenatal care market is expected to witness strong growth as all pregnant women suffer from common health issues such as stretch marks, pigmentation, hair and snail changes, and back pain. Several pregnancy products are available to treat these conditions in the form of creams, gels, and lotions in the U.S. Therefore, the prenatal care market in the country is expected to grow significantly in the next few years. Additionally, the leading players help create awareness regarding availability and use of pregnancy products in the market. These players engage in various marketing tactics and awareness campaigns which is expected to boost the growth of the prenatal care market. Furthermore, approximately 90% women develop stretch marks during pregnancy. This has increased demand for these products to be readily available in the market.

Download PDF Brochure of Report:

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=28484

The global prenatal care market is driven by various factors such as increasing incidence of preterm child births, growing awareness about prenatal care, and rising demand for various prenatal products, therapeutics, diagnostics, and monitoring equipment. Additionally, government initiatives for prenatal and neonatal care are likely to drive the market in the near future. Moreover, increase in distribution channels such as supermarkets, online stores, retail stores, and pharmacies are likely to fuel the growth of the pregnancy products market in the near future. Furthermore, rise in teen pregnancies in Southern United States is projected to propel the prenatal market in the region. Growing awareness about prenatal care has led to increase in expenditure on baby care products to provide the right care to babies. However, the global recession, increase in working women population, and single child family are the factors hampering market growth. Nevertheless, governments in some countries are taking action to offset these restraints by providing subsidies to families with more children.

Request to View TOC of Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=28484

The global prenatal care market has been segmented based on product type, distribution channel, and region. In terms of product type, the market has been segmented into skin toning lotions, body restructuring gels, stressed leg products, breast products, stretch mark minimizers, and dark spot treatment creams. The stretch marks minimizers segment is projected to account for the largest share of the market during the forecast period. Growth of the segment is attributed to increasing popularity and enhanced results shown by these products. Based on distribution channel, the prenatal care market has been segmented into hospital pharmacies, online pharmacies, supermarkets, and drug stores. Geographically, the prenatal care market has been segmented into five major regions: North America, Asia Pacific, Europe, Latin America, and Middle East & Africa. North America is expected to dominate the global market during the forecast period owing to increase in female population and significant rise in the number of pregnancies in the past few years. Around 4 million births take place in the U.S. each year. This is the most developed market for prenatal products, with high average spending among parents-to-be for healthy child.

Major players in the market are Nine Naturals, LLC, Mama Mio US Inc., Clarions Group, Expanscience Laboratories, Inc., and Noodle & Boo.

Request to View Discount –

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=28484

Anti-allergic Therapeutics Market: 2017- Trends, Market: Share, Industry Size, Growth, Opportunities and Forecast to 2025

Anti allergic Therapeutics Market: Overview

Allergy is described as an abnormal or pathologic immune reaction that occurs in response to foreign material. The foreign material include pollen, dust mites, mold spores, pet dander, food, medicine and many more. Allergies can cause a variety of symptoms such as runny nose, sneezing, rashes, swelling, or itching. Symptoms can range from minor to severe. Allergies includes food allergy, allergic asthma, atopic dermatitis, allergic rhinitis, hay fever, and anaphylaxis. Anaphylaxis is a severe and life-threatening reaction that requires immediate medical treatment and hospitalization. If not treated it may be fatal. Allergies can affect anyone, but are more common in children than in adults. People suffering from asthma, or have family history of asthma or allergies are at higher risk of developing different types of allergies. About 50 million Americans suffer from allergic disease. According to World Allergy Organization, around 30-40% of the world’s population is affected with allergic conditions.

Download PDF Brochure of Report:

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=28103

Treatment for allergy includes medicines, allergy shots, and avoiding the substances that causes the allergic reaction. Based on medicines, the anti-allergic therapeutic market is segmented into antihistamine (brompheniramine and cetirizine), corticosteroids (dexamethasone), mast cell stabilizers (cromolyn), decongestants (phenylephrine), and other medicine (Anti-IgE, Leukotriene). First generation antihistamine was discovered back in 1937 for the treatment of allergies. Owing to its sedative side effect, in the early 1990s, second generation antihistamine came into the picture for the treatment of allergies. Second generation antihistamine are mostly preferred because of their non-sedating nature. Corticosteroids first introduced in the 1970s possesses different mechanisms of action but does not repress release of histamine; hence, they are commonly preferred in combination with antihistamines. Patent expiration of leading prescription antihistamine and corticosteroid is leading to the introduction of more generic and OTC products in the anti-allergic therapeutic market. Allergy shots are also known as immunotherapy. Allergy shots segment is expected to expand in the anti-allergic therapeutic market because it is the only treatment that changes the immune system and prevents new allergies from developing. Introduction of newer forms of immunotherapy i.e. ‘sublingual immunotherapy’ also boosts the anti-allergic therapeutic market. For instance, in April 2017, the U.S FDA approved a house dust mite sublingual immunotherapy tablet for treatment of house dust mite-induced allergic rhinitis in adults. Rise in the patient pool suffering from different types of allergies is a major factor driving the market. Changes in lifestyle, increase in environmental pollution, growing demand for advance treatment, and changes in dietary habits have also propelled the anti-allergic therapeutic market. However, high cost of therapy and side effects are the factors restraining the anti-allergic therapeutics market.

Request to View TOC of Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=28103

In terms of geography, the anti-allergic therapeutics market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America and Europe dominated the anti-allergy therapeutics market due to rising percentage of population suffering from allergies. In addition, presence of developed health care infrastructure, rise in environmental pollution, and increasing demand for immunotherapy for treatment have accelerated the growth of the anti-allergy therapeutic markets in these regions. Asia Pacific is an emerging market due to the rising allergic patient population pool, rapid development of health care infrastructure, growing awareness about advance treatment options, and the increase in government expenditure in the health care sector. However, poor patient awareness, lack of proper treatment, and high cost of therapy restrains the growth of the anti-allergic therapeutics market in regions such as Middle East & Africa

Major players operating in the anti-allergic therapeutics market include Allergy Therapeutics, Allergan, Plc., Genentech, Inc., Collegium Pharmaceutical, Inc., McNeil Consumer Healthcare, Strides Arcolab, and Allergopharma GmbH & Co. KG.

Request to View Discount –

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=28103

Phenylketonuria (PKU) Diagnosis and Treatment Market: Estimation, Dynamics, Regional Share, Trends, Competitor Analysis to 2025

Phenylketonuria (PKU) Diagnosis and Treatment Market: Overview

Phenylketonuria is a rare genetic condition that leads to the production of phenylalanine in the body. Phenylalanine is an amino acid present in all proteins and in certain artificial sweeteners. The human body uses enzyme phenylalanine hydroxylase to convert phenylalanine into tyrosine, which is a nonessential amino acid. The human body requires tyrosine to create neurotransmitters, such as epinephrine, norepinephrine, and dopamine.

Download PDF Brochure of Report:

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=26999

Phenylketonuria (PKU) is caused due a defect in the gene which helps to produce phenylalanine hydroxylase. Absence of phenylalanine hydroxylase leads to a buildup of phenylalanine in the body. Timely diagnosis and treatment helps in terminating the symptoms of PKU and avoid brain damage. Phenylketonuria is an inherited genetic condition caused due to a defect in the PAH gene. The PAH gene is responsible for the production of phenylalanine hydroxylase for breakdown of phenylalanine. Increased levels of phenylalanine can occur due to high intake of protein, such as eggs and meat. For an infant to inherit phenylketonuria, both parents must pass on a defective version of the PAH gene.

Classic PKU is the most severe form of phenylketonuria disorder. A newborn with classic PKU appears normal for the first few months. If the newborn is not treated for phenylketonuria in time, it can develop symptoms such as seizures, tremors, or trembling and shaking, stunted growth, hyperactivity, skin conditions, and etc. The other form of phenylketonuria is known as non-PKU hyperphenylalaninemia, which occurs when an infant has higher levels of phenylalanine in the body. Non-PKU hyperphenylalaninemia disorder can have mild symptoms, but in order to prevent intellectual disabilities they need to follow a special diet to prevent disabilities.

Request to View TOC of Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=26999

Phenylketonuria condition is uncommon in the U.S., affecting about 1 in 10,000 to 15,000 newborns every year. The severity of phenylketonuria is rare in the U.S., due the early screening and availability of optimized treatment soon after birth. Phenylketonuria can lead to permanent brain damage and intellectual disabilities within the first few months after the birth and in time lead to behavioral problems among older children. A screening test is performed when an infant is one to two days old and still in hospital. The doctor uses a needle to collect few drops of blood sample from the infant’s heel to run the test for phenylketonuria and other genetic disorders. According to the U.S. FDA, recently approved sapropterin can be used for the treatment of phenylketonuria. Sapropterin helps to lower phenylalanine levels in the body. The medication must be used in combination with a special phenylketonuria meal plan.

Based on product type, the phenylketonuria diagnosis and treatment market has been segmented into drugs and nutrition supplements. Nutrition supplements are widely prescribed by doctors along with specialized diet during the treatment of phenylketonuria. In terms of route of administration, the market has been segmented into oral and parenteral.

Increasing incidence rate of phenylketonuria is a major driver of the global phenylketonuria diagnosis and treatment market. The incidences of phenylketonuria are based on demographics and ethnic groups. Phenylketonuria screening tests used for diagnosis include bacterial inhibition assay, immunoassay, and mass spectrometry analysis for amino acid.

Increasing awareness, growing research in the field of genomics and bioinformatics, changing lifestyle, advancements in the health care industry, and rising per capita income in emerging markets are expected to drive the phenylketonuria diagnosis and treatment market during the forecast period. However, overall high cost of treatment, stringent government regulations, and unfavorable reimbursement are expected to restrain the market.

Geographically, the global phenylketonuria diagnosis and treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the phenylketonuria diagnosis and treatment market due of increasing population, rising number of screening procedures, presence of leading manufacturers, and technological advancements. North America is closely followed by Europe and Asia Pacific. Asia Pacific is an emerging market for phenylketonuria diagnosis and treatment primarily because of increasing health care expenditure in the region and awareness.

Request to View Discount –

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=26999

Key players in the global phenylketonuria diagnosis and treatment market are Cambrooke Therapeutics, Daiichi Sankyo Company Limited, American Gene Technologies International, Inc., Danone Nutricia, Dimension Therapeutics, Inc., Synthetic Biologics, Inc., SOM Innovation Biotech SL, Codexis, Inc., BioMarin Pharmaceutical, Inc., and Erytech Pharma SA, among others.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Cancer Pain Management Market: Outlook, Competitive Landscape and Forecasts to 2025

Cancer Pain Management Market: Overview

The global cancer pain management market is envisaged to gain a telling impetus while riding on the moderate to severe pattern of pain experienced by patients worldwide. Nearly a 70.0% of cancer patients could suffer from chronic pain because of spinal cord injuries, 28.0% due to multiple sclerosis, and 8.0% on account of stroke on a global platform. Besides this, an above 75.0% of the patients are expected to complain of a gradual surge in pain with the progression of the disease. Increase in the count of patients experiencing such pain could put a positive effect on the growth of the market.

With elevating research and development focus, there could be a range of drugs in the pipeline. This is anticipated to bode well for the global cancer pain management market as more drugs could mean a rise in demand.

Download PDF Brochure of Report:

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=26897

From the geographical perspective, the global cancer pain management market is prognosticated to be segregated into key regions, out of which, North America could take a leading position. Better healthcare spending, improved healthcare infrastructure, and presence of leading players are some of the top reasons that the region is predicted to outclass other geographical segments of the market. However, Asia Pacific could make its presence known for cancer pain management on the back of enhanced healthcare services provided to patients and key countries such as India, Brazil, and China exhibiting multiplied investments by their governments. Growing awareness about cancer and its pain management could also contribute to the growth of Asia Pacific.

Pain is an unpleasant emotional, subjective, and sensory experience due to the actual or potential damage caused to cells or tissues of the patients. Pain is the most common symptom in various manifestations that lead patients to seek medical assistance or advice. Cancer is associated with several well-defined acute as well as chronic pain syndromes. Cancer is a complex and potentially fatal disease that is primarily caused through environmental factors resulting into gene mutations affecting critical cell-regulatory proteins. Such changes trigger aberrant cell behavior leading to uncontrolled proliferation of cells (tumor formation) and subsequent destruction of surrounding normal tissues. Tumors are either benign or malignant, while the malignant tumors are characterized by rapid growth, invasiveness, and potential to colonize in distant organs. These tumors exert pressure by pressing on nerves, bones, and other parts of the body causing pain. Cancer pain is also experienced during active cancer therapy and primarily during the advanced stages of cancer.

Request to View TOC of Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=26897

The rising prevalence of cancer across the globe is driving the global cancer diagnostics market. According to the International Agency for Research on Cancer, there were 14.1 million new cases of cancer and 8.2 million deaths recorded globally in 2012. Based on the above statistical information, the World Health Organization (WHO) estimated that by 2025, 19.3 million new cases are expected to occur each year. Rising incidences of cancer and increasing healthcare spending is anticipated to aid the global cancer pain management market. Moreover, the Patient Protection Act and Affordable Care Act amended on March 30, 2010, by the Health Care and Education Reconciliation Act, enhancing the insurance access to more than 25 million U.S. citizens, is eventually estimated to support the growth of cancer pain management.

The pain management methods for cancer used currently, include medication or drugs, nerve blocks, oral morphine therapy, fentanyl patches, and medical systems or devices. Opioids are considered to be the most effective way of pain management, while combined pain management therapies and medication are more effective. The global market for cancer pain management is projected to expand significantly due to advances in technology for better alternatives for pain management and favorable government initiatives and funding. The alarming rise in the rate of cancer prevalence compels healthcare providers to rethink of their goals of treating cancer and also focus on pain management, which is likely to require cancer pain management methods that are specific, efficient, and sensitive. The cancer pain management market can be segmented into treatment type, disease indication, and regions, which is as follows:

By treatment type, the cancer pain management market can be segmented into:

  • Medications
    • Opioids/Narcotics
      • Morphine
      • Fentanyl
      • Others
    • Non-Opioids
      • Acetaminophen
      • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
    • Nerve Blocks
  • Devices or Systems
    • Electrical Stimulation Devices
      • Transcutaneous Electrical Nerve Stimulation (TENS) Devices
      • Neuromuscular Electrical Stimulation (NMES/EMS) Devices
      • Others (Electrotherapy Devices, Combination Devices, etc.)
    • Analgesic Infusion Pumps
      • Intrathecal Infusion Pumps
      • External Infusion Pumps
    • Neurostimulation Devices
      • Spinal Cord Stimulation (SCS) Devices
      • Deep Brain Stimulation Devices
      • Others
    • Radiofrequency Ablation Devices

By disease indication, the cancer pain management market can be segmented into:

  • Lung Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Blood Cancer
  • Others

Request to View Discount –

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=26897

In terms of regions, the cancer pain management market can be into Asia Pacific (APAC), Europe, Middle East & Africa (MEA), North America (NA), and Latin America (LA). Key players operating in the cancer pain management market include Abbott, Boston Scientific Corporation, Baxter, Medtronic plc., and Olympus. Intense competition is driving acquisition and in-licensing agreements, as companies are striving to expand and diversify their product pipeline. Strategic partnership and alliances are commonplace, as companies are aiming to synergize their programs and develop combination pain management therapies.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Tuberculosis Diagnostic Market: Outlook, Competitive Landscape and Forecasts to 2025

Tuberculosis Diagnostic Market: Overview

Tuberculosis is an infectious disease caused by bacteria (Mycobacterium tuberculosis), which is characterized by the growth of tubercles (a small rounded projection specially formed in the bone or on the surface of an animal) in lung. It usually affect the lungs, but also affects other parts of body such as brain, kidney, and spine. There are two types of tuberculosis: latent tuberculosis and active tuberculosis. The condition in which bacteria remain in an inactive state and cause no symptoms is called latent tuberculosis. The condition in which bacteria are in active state and show symptoms is called active tuberculosis. Chronic cough with blood containing sputum, fever, and night sweat are some symptoms of active tuberculosis. Tuberculosis is a contagious disease which spreads through air. Diagnosis of active tuberculosis is done through chest X-rays and microscopic examination of culture body fluids. Latent tuberculosis diagnosis is done through tuberculin skin test or blood test. People with prolonged and close contact with tuberculosis infected people, already suffering from human immunodeficiency virus (HIV) infection and have weak immune system are particularly at high risk of developing tuberculosis. According to the World Health Organization, 10.4 million people are infected with tuberculosis globally i.e., 28,500 people/day and 1.8 million people have died from tuberculosis, including 400,000 with HIV positive tuberculosis i.e., 4,900/day. Tuberculosis is among the top 10 causes of death globally.

Download PDF Brochure of Report:

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=26621

Based on test, the tuberculosis diagnostic market has been segmented into diagnostic laboratory method (culture based tests, nucleic acid testing, serological tests, interferon-gamma release assays, phage-based tests, and others) and radiographic method (chest X-ray). The diagnostic laboratory method segment holds significant market share because it is cost effective and easy to perform as compared to radiographic method. However, compromised accuracy and longer processing time are factors that restrain the diagnostic test method segment. Hence healthcare industries are looking for the advanced technique to overcome from the problem of diagnostic laboratory. Advances in X-ray systems, especially mobile radiography and portable equipment such as Practix 400 Plus, are likely to fuel the growth of the tuberculosis diagnostic market. Increase in morbidity and mortality rate and high unmet needs to current diagnostic tools such as no rapid test available to detect the resistance of anti-tuberculosis drugs(rifampin and isoniazide), no rapid test available to detect the latent tuberculosis , and other than DNA there is no good biomarker are the opportunities that boosts the tuberculosis diagnostic market. However, most of the tests require a good quantity of sputum which some patients are unable to produce. Moreover, high cost of diagnosis and requirement of highly developed infrastructure to perform the diagnostic tests are the major factors restraining the market.

Request to View TOC of Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=26621

Geographically, Asia Pacific dominated the global tuberculosis diagnostic market because of large patient pool (about 60% of the world’s population). According to the World Health Organization, countries such as China, India, Indonesia, Nigeria, Pakistan, and South Africa are affected with tuberculosis. Increase in awareness about the disease, better purchasing power, and developed health care infrastructure boost the growth of the tuberculosis diagnostic market in North America. Affordability issues, lack of availability of diagnostic tools, and poor patient education are factors restraining the market in Middle East & Africa.

Key players in the tuberculosis diagnostic market include Thermo Fisher Scientific, Inc., Hologic Company, Alere, Inc., F. Hoffmann-La Roche AG, Becton, Dickinson and Company, bioMérieux SA, Hain Lifescience GmbH, Sanofi S.A., Cepheid Inc., and QIAGEN.

Request to View Discount –

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=26621

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Acute Heart Failure Market: 2025: Healthcare Industry Demand, Growth, Analysis & Forecast

Acute Heart Failure Market: Overview

Heart failure occurs when the heart is unable to pump enough blood to meet the body’s demand. This can be chronic, taking place slowly over time, or acute, occurring suddenly. Acute heart failure is defined as the rapid development of or change in symptoms pointing to heart failure requiring urgent medical attention and usually hospitalization. It is a physiological condition which adversely impacts the pumping efficiency of the cardiac muscles. Fluid accumulates around the heart and the ventricles fail to pump sufficient blood to all the organs. This eventually leads to deposition of the fluid in the lungs, abdomen, liver, and lower body. According to epidemiologic statistics by Novartis Pharmaceuticals, about 62 million adults worldwide died of heart failure in 2015 and this number is expected to rise. One person in five at the age of 40 runs the risk of developing heart failure, with over 1 million hospitalizations reported annually in Europe are accounted for by heart failure.

Download PDF Brochure of Report:

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=25925

The increasing prevalence of diseases and unmet medical needs have created additional scope for the acute heart failure market. Drivers of this market include poor diet, lack of exercise, changing lifestyles, increasing stress, unhealthy weights, and rising levels of smoking & alcohol consumption. The incidence of one or more diseases such as diabetes mellitus, obesity, coronary artery diseases, sleep apnea, heart defects, irregular heartbeats, and kidney problems has a synergistic effect on the prevalence of acute heart failure, further contributing to the market.

The acute heart failure market can be segmented by type of treatment into the following categories: surgery, medicines, and medical devices. Common types of surgery include heart valve replacement, coronary artery bypass grafting surgery, and heart transplant. Classes of drugs used in the management of acute heart failure include angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers, beta blockers, digoxin, diuretics, aldosterone antagonists, nitrates, inotropic agents, and anticoagulants. ACE inhibitors, angiotensin II receptor blockers, and diuretics are major contributors to the acute heart failure market. Cardiorentis’ ularitide and Novartis’ serelaxin represent new treatment options for acute heart failure. Both are recombinant forms of human proteins intended to be used in addition to intravenous administered loop diuretics which are the current standard-of-care for acute heart failure.

Request to View TOC of Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=25925

Implantable left ventricular assist devices (LVAD), biventricular pacemakers, implantable cardioverter-defibrillators (ICDs), and heart pumps are the medical devices used in acute heart failure. Unmet medical needs such as safe & effective therapy and the increasing number of acute heart failure patients boost the demand for these devices. However, stringent regulatory requirements and the high cost of these devices negatively impact the market.

Geographically, the acute heart failure market is distributed over North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. Among these, North America and Europe dominate the market. The prevalence of heart diseases is high in Eastern Europe and is increasing in parts of Asia and South America owing to the growing incidence of cardiac disorders, aging population, lack of exercise, diet-containing high fat & salt content, stress, and smoking. In Asia Pacific, China, Japan, Malaysia, and India constitute major shares in the acute heart failure market on account of the growing financial potential of individuals.

Key players in this market include Pfizer, GlaxoSmithKline plc. Novartis International AG, Biovail, Bristol Mayers Squibb Company, MSD, AstraZenica, Abiomed Inc., Symplmed, Berlin Heart GmbH, Biotronik SE & Co. KG, Boston Scientific Corp., HeartWare International Inc., Jarvik Heart Inc., LivaNova PLC, Medtronic plc, ReliantHeart Inc., St. Jude Medical Inc., and Cardiokinetix.

Request to View Discount –

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=25925

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Thermoform Plastic Pharma Packaging Market: Latest Report with Forecast 2017 – 2025

Thermoform Plastic Pharma Packaging Market: Overview

Thermoform plastic pharma packaging is a technique which allows the inhibition of pharmaceutical products starting from their manufacturing process in a unit until they are put to use. The role of pharmaceutical packaging is to provide protection for surgical devices, life-saving drugs, nutraceuticals, blood products, powders, poultices, solid & semisolid dosage forms, and liquid & dosage forms. Thermoform plastics are ideal packaging material due to their aesthetic appearance and low cost. Packaging is the key to safety, success, and sale. Similar to other packed consumables, pharmaceutical packaging must check off requirements such as product quality, protection, patient comfort, speedy processing, identification, display, and security needs. Research and development in this sector is always dependent on the packaging technology which assures the sustaining reliability of pharmaceuticals during shipment, storage, and delivery.

Download PDF Brochure of Report:

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=24089

The thermoform plastic pharma packaging market is driven by motives such as prevention of counterfeit pharmaceutical drugs, prevention of product tampering, dispensing accuracy, promotion of patient compliance with product dosage schedules, and innovations leading to cost & time reduction. In the pharmaceutical industry, manufacturing and research technologies are constantly developing, with the ethics of environmental needs, novel medicaments, and patient compliance leading to progress in delivery and packaging systems. Increased investment in research & development and formulation of large molecules in biopharmaceutical drugs are in the pipeline and predicted to propel the thermoform plastic pharma packaging market.

The global market is segmented by type into the following categories: clamshell packaging, blister packaging, skin packaging, and others (trays and tubes). Clamshell packaging is a one-piece ampoule containing two splits joined by a center area that permits the arrangements to come together to close. Blister packaging is the pharmaceutical industry’s first choice as it is cost-effective and easy to produce in high volumes. The products are thereby protected from moisture and gas and lead a long shelf life. Skin packaging is used for topical creams, ointments, and lotions.  Based on material, the market for thermoform plastic pharma packaging is divided into the following segments: aluminum, plastic, and paper & paperboard. Plastic materials such as polyethylene, polypropylene, polyvinyl chloride, polystyrene, and nylon are used in immense proportions for the production of thermoform plastic pharma packaging.

Request to View TOC of Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=24089

Geographically, the global market is distributed over five key regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global thermoformed plastics pharma packaging market owing to the increasing demand for convenient medications and drugs caused by the busy schedules of people and changing lifestyles attached with associated regulations over pharmaceutical medication packaging. Europe is the second leading market for thermoform plastic pharma packaging on account of the rising focus on pharmaceutical packaging quality along with promising regulatory support. Asia Pacific is a highly attractive region for thermoform plastic pharma packaging due to the low labor cost for manufacturing in India and China.

Key players operating in the thermoform plastic pharma packaging market include Placon, VisiPak, Nelipack Healthcare, Prent Corporation, Key Packaging, Lacerta Group, Inc., Innovative Plastics Inc., Bemis Company, Inc., Amcor Limited, CN Thermforming Machine, Walter Drake Inc., Barger., Plastic Ingenuity, Shanghai Jornen Machinery Co., Ltd., and China Good Quality Automatic Blister Packing Machine Supplier. Increasing competition among key players due to the rising demand for advanced pharmaceutical packaging is projected to drive the thermoform plastic pharma packaging market during the forecast period.

Request to View Discount –

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=24089

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

HIV-associated Lipodystrophy Market: Report 2017 and Future Opportunity Assessment 2025

HIV associated Lipodystrophy Market: Overview

Changes in body fat concentration, affecting people with HIV, is known as HIV-associated lipodystrophy. The exact causes of this condition is currently unknown, but research suggests that this disorder can occur either due to HIV infection or as a consequence of side effects associated with drugs used in HIV infection treatment, such as Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs), Protease Inhibitors (PIs), etc. The lipodystrophy condition is characterized by metabolic abnormalities, including insulin resistance, and dyslipidemia. The HIV-associated lipodystrophy groups together different clinical conditions, which are lipoatrophy and lipoaccumulation. Lipoatrophy is associated with subcutaneous fat loss, whereas lipoaccumulation is the increase in visceral fat. In certain cases, HIV-associated lipodystrophy may occur as a combination of these two conditions; thus, its treatment and prevalence measurement are difficult.

Download PDF Brochure of Report:

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=22925

The global HIV-associated lipodystrophy market is witnessing unprecedented dynamics. Several research studies are directed toward finding out the link between the two mechanisms of lipodystrophy in such a way that a single mechanism will can occur for redistribution of fat. Improving healthcare infrastructure and increasing incidence rates of HIV/AIDS patients globally are expected to drive the growth of the global HIV-associated lipodystrophy market. However, lower adoption of therapeutic treatment and demand for constant nutritional supply from patients is anticipated to restrain the growth of the global HIV-associated lipodystrophy market.

The global HIV-associated lipodystrophy market has been segmented based on lipodystrophy type, therapeutic class, and distribution channels. On the basis of lipodystrophy type, the market has been classified into lipoatrophy and lipoaccumulation. In terms of therapeutic class, the market is divided into anabolism modulators, insulin resistance modulators, mitochondrial antioxidants (L-carnitine), and other miscellaneous metabolic agents. Anabolism modulators are further bifurcated into growth hormones and anabolic steroids. Insulin resistance modulators can be sub-segmented into metformins, thiazolidinediones, and others. Growth hormones are widely used for the treatment of HIV-associated lipodystrophy due to their efficacy. Based on distribution channels, the global HIV-associated lipodystrophy market is categorized into hospital pharmacy stores, retail pharmacy stores, and online pharmacies. Hospital pharmacy stores are expected to account for higher market share due to their ease of connectivity, and trend of utilization of newly advanced products among end-users including physicians and patients.

Request to View TOC of Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=22925

There is a lack of evidence-based strategies for the treatment of HIV-associated lipodystrophy. The treatment switch between the two lipodystrophy conditions, along with HIV drugs that possess lower mitochondrial toxicity, is an emerging trend in the global HIV-associated lipodystrophy market. There is a large patient pool in emerging countries, where lower drug affordability is a major challenge for market penetration of HIV-associated lipodystrophy therapeutics. Thus, the introduction of affordable drugs by local manufacturers serves as a major opportunity in the global HIV-associated lipodystrophy market. However, the other treatment options such as cosmetic surgeries also arrests the growth of the global HIV-associated lipodystrophy market.

On the basis of geography, the global HIV-associated lipodystrophy market has been divided into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is expected to grow at a high CAGR owing to factors like large patient pool, increasing demand for low cost drugs, rising awareness of the treatment options for HIV-associated lipodystrophy, and adoption of better healthcare facilities. North America is projected to dominate the global HIV-associated lipodystrophy market due to increasing adoption of new and technologically advanced products, high per capita health expenditure, and substantial investments in research and development for efficient treatment options.

Request to View Discount –

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=22925

Key players in the global HIV-associated lipodystrophy market are Novelion Therapeutics Inc., Theratechnologies Inc., Gilead Sciences Inc., GlaxoSmithKline plc (Viiv Healthcare Group of Companies), AbbVie Inc., Bristol-Myers Squibb Company, and AstraZeneca plc, among others.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Page 1 of 1191

Powered by WordPress & Theme by Anders Norén